<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00046852</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000256870</org_study_id>
    <secondary_id>MSGCC-0065</secondary_id>
    <secondary_id>UPCC-6401</secondary_id>
    <secondary_id>NCI-V02-1709</secondary_id>
    <nct_id>NCT00046852</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>High-Dose Therapy and Autologous Blood Stem Cell Transplantation (ASCT) Followed by Post-Transplant Immunotherapy With Costimulated Autologous T-Cells in Conjunction With Pneumococcal Conjugate Vaccine Immunization for Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland Greenebaum Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell&#xD;
      transplantation and immunotherapy may allow the doctor to give higher doses of chemotherapy&#xD;
      drugs and kill more cancer cells. Biological therapies use different ways to stimulate the&#xD;
      immune system and stop cancer cells from growing.&#xD;
&#xD;
      PURPOSE: Randomized phase I/II trial to study the effectiveness of combining chemotherapy&#xD;
      with peripheral stem cell transplantation followed by immunotherapy in treating patients who&#xD;
      have multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of expanding ex vivo autologous T cells and infusing these&#xD;
           cells after high-dose chemotherapy and autologous peripheral blood stem cell rescue in&#xD;
           patients with multiple myeloma.&#xD;
&#xD;
        -  Determine the response rate and progression-free survival of patients who receive&#xD;
           anti-CD3/anti-CD28 expanded autologous T cells on either day 14 or day 100&#xD;
           post-transplantation.&#xD;
&#xD;
        -  Compare response and survival rates of these patients to historical controls.&#xD;
&#xD;
        -  Determine the optimal schedule for pneumococcal conjugate vaccine (PCV) to induce an&#xD;
           anti-pneumococcal immune response post-transplantation in these patients.&#xD;
&#xD;
        -  Determine whether &quot;vaccine education&quot; of antigen-presenting cells (APCs) in the stem&#xD;
           cell graft results in an earlier and/or enhanced immune response than with a graft&#xD;
           containing &quot;non-educated&quot; APCs in these patients.&#xD;
&#xD;
        -  Determine whether an infusion of T cells presensitized to the PCV and expanded ex vivo&#xD;
           contributes to the anti-pneumococcal immune response in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study.&#xD;
&#xD;
      Patients receive cyclophosphamide IV over 12 hours on day 1 and filgrastim (G-CSF)&#xD;
      subcutaneously (SC) daily beginning on day 2. Patients undergo leukapheresis to collect&#xD;
      mononuclear cells for autologous T cells (ATCs) and peripheral blood stem cells (PBSCs). ATCs&#xD;
      are generated by ex vivo expansion for 8-14 days and selection for CD3+/CD28+ cells.&#xD;
&#xD;
      Patients then receive high-dose therapy comprising carmustine IV over 2 hours on day -2 and&#xD;
      melphalan IV over 20 minutes on day -1 or melphalan IV alone on days -2 and -1 (or day -1&#xD;
      only). Autologous PBSCs are reinfused on day 0. Patients also receive G-CSF SC beginning on&#xD;
      day 1 and continuing until blood counts recover.&#xD;
&#xD;
      Patients who choose to receive pneumococcal conjugate vaccine (PCV) are randomized to 1 of 4&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive PCV intramuscularly prior to transplantation (10-14 days before&#xD;
           lymphocyte collection) and post-transplantation (1 and 3 months) plus costimulated ATCs&#xD;
           IV over 20-60 minutes around day 12-14 post-transplantation.&#xD;
&#xD;
        -  Arm II: Patients receive PCV as in arm I but receive ATCs around day 100&#xD;
           post-transplantation.&#xD;
&#xD;
        -  Arm III: Patients receive PCV post-transplantation only (at 1 and 3 months) plus ATCs as&#xD;
           in arm I.&#xD;
&#xD;
        -  Arm IV: Patients receive PCV as in arm III and ATCs as in arm II. Patients who choose&#xD;
           not to receive the PCV receive ATCs on about day 12-14 after PBSC transplantation.&#xD;
&#xD;
      All patients are offered standard pneumococcal polysaccharide vaccine at 12 months.&#xD;
&#xD;
      Patients are followed twice weekly until day 60, weekly for 4 months, monthly for 6 months,&#xD;
      and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 16-46 patients will be accrued for this study within 14 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Infection</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pneumococcal polyvalent vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic tumor infiltrating lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma requiring systemic treatment&#xD;
&#xD;
          -  No obvious myelodysplastic changes in the marrow&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 80&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 (ECOG 3-4 allowed if based solely on bone pain)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No chronic active hepatitis&#xD;
&#xD;
          -  No liver cirrhosis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 3.0 mg/dL&#xD;
&#xD;
          -  No dialysis&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 45% unless no evidence of untreated clinically significant functional&#xD;
             impairment&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 and FVC at least 50% of predicted&#xD;
&#xD;
          -  Total lung capacity at least 50% of predicted&#xD;
&#xD;
          -  DLCO at least 50% of predicted&#xD;
&#xD;
          -  Mild to moderate pulmonary impairment (lower DLCO) allowed but patients would not&#xD;
             receive study carmustine&#xD;
&#xD;
          -  Patients unable to complete pulmonary function test due to bone pain or fracture must&#xD;
             have high-resolution CT scan of the chest and arterial partial pressure of oxygen&#xD;
             greater than 70&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No active infections requiring IV antibiotics&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior pulse dexamethasone (1-2 courses) allowed&#xD;
&#xD;
          -  Concurrent pulse dexamethasone allowed during mobilization therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron P. Rapoport, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland Greenebaum Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marlene and Stewart Greenebaum Cancer Center, University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <keyword>infection</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

